Figure 3.

Median OS from date of locally advanced or metastatic disease in patients not treated with an ICI (N = 272 with available data). The median OS in the high CTLA-4 (N = 39) expressed cohort was 46.8 months (28.8 to NE, 95% CI) versus the median OS in the low/moderate CTLA-4 (N = 233) expressed cohort of 42 months [31.2–49.2, 95% CI; HR for high versus low/moderate expression cohort (95% CI) = 0.8 (0.5–1.4, 95% CI; p value = 0.49)]. These results indicate that high versus non-high CTLA-4 was not prognostic for OS.

*NE denotes not estimable.

ICI, immune checkpoint inhibitors; OS, overall survival.